Nasdaq GlobeNewswire

SpeeDx and Serosep sign UK and Ireland distribution agreement

Del

SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed  Plex PCR ® and  Resistance Plus ® molecular diagnostic tests across the region.

The agreement provides Serosep customers with access to SpeeDx's proprietary technology for infectious disease diagnostics, in line with Serosep's goal of improving lives while supporting the everyday struggles faced by laboratories. The SpeeDx portfolio includes the market-leading  Resistance Plus MG assay - for simultaneous detection of Mycoplasma genitalium and genetic markers for azithromycin resistance - as well as a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Further  Resistance Plus assays will be released later this year - including a test for gonorrhoea - along with a comprehensive  Plex PCR multiplex panel for respiratory virus testing.

"There's an obvious synergy between SpeeDx and Serosep, and we share the common goal of offering innovative solutions to our customers," said Colin Denver, CEO of SpeeDx. "This strategic distribution agreement will extend our reach in Europe as we continue to expand our test portfolio." 

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. Currently, SpeeDx markets the only CE-marked and TGA approved commercial molecular test for the STI M. genitalium (ResistancePlus® MG) that combines detection of the disease with detection of markers for antibiotic resistance.

For more information about SpeeDx please see: http://plexpcr.com

About Serosep

In 1997, Serosep Ltd. began distributing diagnostics solutions for Clinical Microbiology, Histopathology and Environmental Laboratories. The knowledge and experience gained over years of manufacturing and distributing to clinical laboratories has allowed Serosep Ltd to understand and appreciate the daily struggles and restraints faced by laboratories on a daily basis. Serosep very early developed a reputation as an innovative company that was constantly seeking to improve the lives of its customers by offering easy to use diagnostic solutions. Today, Serosep is a thriving company with a constantly expanding workforce, selling products sold across five continents and boasts sales in 35 countries worldwide.

For more information about Serosep please see: http://www.serosep.com/

Contact:

Madeline O'Donoghue
madelineo@speedx.com.au




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SpeeDx Pty Ltd via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Elite Petro & Gas, a new brand by Elite Capital & Co. Limited15.10.2018 16:15Pressemelding

LONDON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Today at Elite Petro & Gas headquarters in the City of London, Dr. Faisal Khazaal (Chairman) and Mr. George Matharu (President) announced the official launch of this new Division within Elite Capital & Co. Limited, which was setup to provide Finance, Trading and Advisory services in the global Oil and Gas markets. “Elite Petro & Gas is a Finance, Trading and Advisory firm with a focus on downstream activities in the global Oil and Gas markets. We are a results-driven business, working closely with our clients to deliver tangible solutions and outcomes.” Mr. George Matharu, President of Elite Petro & Gas, said. The oil and gas industry is facing challenging times, particularly from changes in the political landscape and increased price volatility. Understanding the nuances of working internationally, often in emerging economies and less stable regimes, is key to ensuring that business risks are appropriately managed. The Elite Petro & Gas (“EPG”

Prof. Dr. C. Oliver Kappe is awarded the 2018 IUPAC-ThalesNano Prize for Flow Chemistry15.10.2018 16:08Pressemelding

KARLSRUHE, Germany and BUDAPEST, Hungary and GRAZ, Austria, Oct. 15, 2018 (GLOBE NEWSWIRE) -- The 2018 IUPAC-ThalesNano prize has been awarded to Professor C. Oliver Kappe. The prize will be presented at the 15th International Conference on Microreaction Technology (IMRET15) in Karlsruhe on October 21, 2018. The award address will be delivered at the Flow Chemistry Europe Conference in Cambridge, UK on February 26th, 2019. The prize consists of an award of $10,000 US Dollars. Professor Kappe is Professor of Chemistry at the University of Graz (Austria) and Scientific Director for Continuous Flow Synthesis and Processing (CC Flow) at the Research Center Pharmaceutical Engineering GmbH (RCPE). Professor Kappe has over 400 publications in the areas of continuous flow chemistry, application of microreactors, process intensification, and microwave-assisted reactions. He and his team have published syntheses with challenging systems and chemistry. He has served as an Ambassador for Flow Chem

Gunvor Closes Innovative US $745 Million Facility Linked to Sustainability Targets15.10.2018 12:00Pressemelding

Related savings will go to support new Gunvor Foundation GENEVA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Gunvor Group (“Gunvor”) has closed an innovative US $745 million secured borrowing base facility (“Facility”) that includes performance commitments related to Gunvor’s sustainability targets. Gunvor is the first energy commodities trading company to close a financing in which the interest rate will be dependent on the company’s year-on-year improvements in areas such as transparency, governance and the environment. The Facility, originally launched at US $625 million in 2012, was a renewal to provide for the working capital requirements of the company’s Antwerp and Rotterdam refineries. It was significantly oversubscribed to US $745 million through the addition of new lenders. The Facility was arranged by ING Bank, who acted as sole Coordinator and Active Bookrunner while maintaining its roles as Security Agent, Facility Agent and Fronting Bank. The structure for the sustainability target

Nasdaq Launches ESG futures in the Nordics15.10.2018 10:00Pressemelding

STOCKHOLM, Sweden, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of futures based on the recently launched OMXS30 ESG Responsible index (OMXS30ESG). The product is the first exchange listed and ESG compliant index future in the world. “In recent years we have seen institutions increase efforts to integrate sustainability into their investment strategies, with the Nordic region being in the forefront of this trend,” says Alessandro Romani, Head of European Equity Derivatives at Nasdaq. “Those looking to invest in a more sustainable way need more investment products based on established and liquid indexes. Our existing OMXS30 index future contract is among the most traded in Europe and we expect to see the same interest for the ESG version.” The OMXS30ESG Index was developed in cooperation with a number of leading Nordic asset managers, including Swedbank Robur. “At Swedbank, innovation and constant development are an important part of the business, a

Telix and ANMI Expand PSMA Imaging Partnership15.10.2018 00:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has expanded its partnership with Advanced Nuclear Medicine Ingredients SA (“ANMI”) for the 68Ga-HBED-CC-PSMA-11 (68Ga-PSMA) cold kit. The 68Ga-PSMA kit is developed by ANMI and commercialized by Telix for the US market where it is marketed as illumetTM . In response to considerable clinical interest in the illumetTM product, Telix has commenced scale-up manufacturing in the United States, following the recent filing of a drug master file (DMF) and the launch of several major clinical trials using the product, including the 750 patient VISION phase III trial (Endocyte, Inc.) and a 500-patient phase II study at Memorial Sloan Kettering C

Brookfield Asset Management 2018 Third Quarter Results Conference Call And Webcast12.10.2018 15:33Pressemelding

Date: Thursday, November 8, 2018 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Third Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2018 Third Quarter Conference Call & Webcast on Thursday, November 8, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial (877) 255-3077 toll free in North America, or for overseas calls please dial (647) 252-4453 at approximately 10:50 a.m. The Conference Call will also be Webcast live at htt

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom